[HTML][HTML] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority …
D Dearnaley, I Syndikus, H Mossop, V Khoo… - The Lancet …, 2016 - thelancet.com
Background Prostate cancer might have high radiation-fraction sensitivity that would give a
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
[HTML][HTML] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority …
D Dearnaley, I Syndikus, H Mossop, V Khoo… - The Lancet …, 2016 - ncbi.nlm.nih.gov
Background Prostate cancer might have high radiation-fraction sensitivity that would give a
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 …
D Dearnaley, I Syndikus, H Mossop, V Khoo, A Birtle… - 2016 - christie.openrepository.com
Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic
advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy …
advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy …
[引用][C] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority …
D Dearnaley, I Syndikus, H Mossop, V Khoo… - Lancet …, 2016 - eprints.ncl.ac.uk
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate
cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial - ePrints …
cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial - ePrints …
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 …
D Dearnaley, I Syndikus, H Mossop, V Khoo, A Birtle… - 2016 - repository.icr.ac.uk
BACKGROUND: Prostate cancer might have high radiation-fraction sensitivity that would
give a therapeutic advantage to hypofractionated treatment. We present a pre-planned …
give a therapeutic advantage to hypofractionated treatment. We present a pre-planned …
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 …
D Dearnaley, I Syndikus, H Mossop… - The Lancet …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Prostate cancer might have high radiation-fraction sensitivity that would give a
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
[PDF][PDF] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority …
D Dearnaley, I Syndikus, H Mossop, V Khoo, A Birtle… - 2016 - smeo.org.mx
Background Prostate cancer might have high radiation-fraction sensitivity that would give a
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
[引用][C] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority …
D Dearnaley, I Syndikus, H Mossop, V Khoo… - The Lancet …, 2016 - cir.nii.ac.jp
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate
cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial | CiNii …
cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial | CiNii …
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 …
D Dearnaley, I Syndikus, H Mossop, V Khoo… - The Lancet …, 2016 - infona.pl
Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic
advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy …
advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy …
[PDF][PDF] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority …
D Dearnaley, I Syndikus, H Mossop, V Khoo… - Lancet …, 2016 - researchmgt.monash.edu
Background Prostate cancer might have high radiation-fraction sensitivity that would give a
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …